Cholesterol Levels Have Been Dropping Since 2013 Guidelines
Implementation of guidelines for lipid management in 2013 correlated with a reduction in mean total cholesterol, triglyceride, and LDL-C levels.
Cholesterol
Alirocumab Safety Profile Similar Regardless of MI, Ischemic Stroke Status
In patients with prior myocardial infarction (MI)/ischemic stroke, treatment with alirocumab is associated with a reduction in low-density lipoprotein cholesterol (LDL-C), as well as reductions in lipoprotein(a), apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C), according to study results published in the Journal of Clinical Lipidology. In addition, efficacy and safety results were similar in patients…
Synopsis of the Updated AHA/ACC Guideline for ASCVD Risk Reduction
The AHA/ACC published a new clinical practice guideline on managing cholesterol and provided a risk assessment report on primary prevention of ASCVD.
LDL and DLCNC Score May Identify Familial Hypercholesterolemia
A low-density lipoprotein-cholesterol level >4.9 mmol/L in addition to the Dutch Lipid Clinic Network Criteria score may help identify probable/definite or possible familial hypercholesterolemia.
Target LDL-C Thresholds Not Met in One-Third of Patients on Statins
Not reaching LDL-C thresholds places patients at increased risk for cardiovascular events.
AHA/ACC Release Updated Guidelines for Cholesterol Management
Updated cholesterol guidelines offer more personalized cardiovascular disease risk assessment.
Familial Hypercholesterolemia Benefits From Genetic Screening
Genetic screening for familial hypercholesterolemia would improve the likelihood of a definitive diagnosis and may help clinicians choose the appropriate therapy for patients.
FDA Issues CRL Rejecting Waylivra Approval for Familial Chylomicronemia Syndrome
“We are extremely disappointed with the FDA’s decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS,” said Akcea CEO, Paula Soteropoulos.
Alirocumab Labeling Updated With Dosing for HeFH Patients Undergoing LDL Apheresis
The dosing recommendation was based on data from a double-blind, placebo-controlled study conducted in 62 patients with HeFH undergoing LDL apheresis.
Nutraceuticals May Benefit Patients Who Are Statin Intolerant
Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.
-
Loading...
-
Loading...
Next post in Dyslipidemia
